Kolb, Antonia; Kulis-Mandic, Ana-Marija; Klein, Matthias et al.
Constitutive expression of the transcriptional co-activator IκBζ promotes melanoma growth and immunotherapy resistanceNATURE COMMUNICATIONS. Bd. 16. H. 1. 2025
Beumer, Niklas; Imbusch, Charles D.; Kaufmann, Tamara et al.
DNA hypomethylation traits define human regulatory T cells in cutaneous tissue and identify their blood recirculating counterpartsNATURE IMMUNOLOGY. 2025
Bauer, Juliane; Hegewald, Janice; Rossnagel, Karin et al.
Incidence of type 2 diabetes and metabolic syndrome by Occupation-10-Year follow-up of the Gutenberg Health StudyBMC PUBLIC HEALTH. Bd. 25. H. 1. 2025
Kardell, Oliver; Gronauer, Thomas; von Toerne, Christine et al.
Multicenter Longitudinal Quality Assessment of MS-Based Proteomics in Plasma and SerumJOURNAL OF PROTEOME RESEARCH. Bd. 24. H. 3. 2025 S. 1017-1029
Mirzac, Daniela; Bange, Manuel; Kunz, Sebastian et al.
Targeting pathological brain activity-related to neuroinflammation through scRNA-seq for new personalized therapies in Parkinson's diseaseSIGNAL TRANSDUCTION AND TARGETED THERAPY. Bd. 10. H. 1. 2025
Declercq, Arthur; Devreese, Robbe; Scheid, Jonas et al.
TIMS<SUP>2</SUP>Rescore: A Data Dependent Acquisition-Parallel Accumulation and Serial Fragmentation-Optimized Data-Driven Rescoring Pipeline Based on MS<SUP>2</SUP>RescoreJOURNAL OF PROTEOME RESEARCH. Bd. 24. H. 3. 2025 S. 1067-1076
Gabele, Anna; Sprang, Maximilian; Cihan, Mert et al.
Unveiling IRF4-steered regulation of context-dependent effector programs in CD4+T cells under Th17-and Treg-skewing conditionsCELL REPORTS. Bd. 44. H. 3. 2025
Huang, Bo; Bopp, Tobias; Li, Guideng
8th Sino-German symposium on immunology: fostering mutual trust and collaborative endeavors for advancing immunological scienceCELLULAR & MOLECULAR IMMUNOLOGY. Bd. 21. H. 7. 2024 S. 798-799
Dahm, Katrin; Vijayarangakannan, Parthiban; Wollscheid, Hans-Peter et al.
Atypical MAPKs in cancerFEBS JOURNAL. Bd. 292. H. 9. 2024 S. 2173-2188
Meuth, Sven G.; Wolff, Stephanie; Mueck, Anna et al.
Different Treatment Outcomes of Multiple Sclerosis Patients Receiving Ocrelizumab or OfatumumabANNALS OF NEUROLOGY. Bd. 97. H. 3. 2024 S. 583-595